A California-based medical technology startup, SoundHealth Inc., has secured $7 million in seed funding to support the commercialization and marketing of SONU, an innovative wearable medical device designed for the treatment of moderate to severe nasal congestion.
The congestion often occurs as a result of an allergic reaction or non-allergic rhinitis.
Recently launched by SoundHealth, SONU is the world’s first AI-enabled medical device of its kind to receive De Novo approval from the US Food and Drug Administration(FDA).
According to SoundHealth’s announcement, the seed round was co-led by Moai Capital and J4 Ventures, with the support of other investors, including TeleSoft Partners, TechU Ventures, Tau Ventures, and Rhythm Venture Capital.
As part of the investment deal, Peter Moran, a seed investor in SoundHealth and an early-stage investor in digital health and wellness companies, will join Sound Health’s board.
According to Dr. Paramesh Gopi, founder and CEO of SoundHealth, the new investment will also support the company’s product launch and advance its pipeline of indicators for the novel SONU device.
SONU—An Innovative AI-powered Wearable Medical Device
SONU has been developed to provide a non-pharmaceutical at-home treatment for nasal congestion patients who are 22 years and older. The device is effective against many maladies without the common side effects of pharmaceutical approaches.
The patented medical devices leverage acoustic vibrational energy to ease nasal congestion, allowing the affected individuals to breathe and sleep better. According to SoundHealth, this approach has been used in the past and has proven effective in relieving symptoms of nasal congestion.
SONU achieves its effectiveness by modulating autonomic input directed to the nasal mucosa, triggering anti-inflammatory and decongestant effects on nasal passages.
Additionally, it uses AI to deliver personalized frequencies based on the patient’s anatomy to provide relief within minutes.